HIV Prevention
Conditions
Brief summary
DatAIDS prevention is a cohort study of HIV prevention in over 23 HIV sites in France including overseas, aiming to describe HIV prevention in every aspect including HIV screening, STI and hepatitis screening, post-exposure prophylaxis and pre-exposure prophylaxis
Interventions
None listed
Sponsors
DatAids
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Male and female over 18 years old, * HIV negative * Attending for : * HIV screening * Hepatitis screening * STI screening / treatment * Blood, body fluid or sexual exposure * Post-exposure prophylaxis * Pre-exposure prophylaxis * Signed consent
Exclusion criteria
* HIV-infection * Refusal to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients enrolled for HIV prevention in the cohort | From date of enrollment, through study completion, an average of 1 year | Demographics, risk factors clinical and biological characteristics, treatment of patients enrolled for HIV prevention in the cohort |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of persons enrolled for post-exposure prophylaxis in the cohort | From date of enrollment, through study completion, an average of 1 year | Demographics, risk factors clinical and biological characteristics, treatment of patients attending for post-exposure prophylaxis in the cohort |
| Proportion of persons enrolled for hepatitis screening in the cohort | From date of enrollment, through study completion, an average of 1 year | Demographics, risk factors clinical and biological characteristics, treatment of patients attending for hepatitis screening in the cohort |
| Proportion of persons enrolled for pre-exposure prophylaxis in the cohort according to national French guidelines | From date of enrollment, through study completion, an average of 1 year | Adequation between prevention practices and guidelines |
| Proportion of persons enrolled for pre-exposure prophylaxis in the cohort | From date of enrollment, through study completion, an average of 1 year | Demographics, risk factors clinical and biological characteristics, treatment of patients attending for pre-exposure prophylaxis in the cohort |
| Incidence of STIs | From date of enrollment, through study completion, an average of 1 year | — |
| Incidence of hepatitis | From date of enrollment, through study completion, an average of 1 year | — |
| Proportion of persons enrolled for post-exposure prophylaxis in the cohort according to national French guidelines | From date of enrollment, through study completion, an average of 1 year | Adequation between prevention practices and guidelines |
Countries
France, Guadeloupe, Martinique
Contacts
Primary ContactPascal Pugliese, MD
Backup ContactSolène Secher
Outcome results
None listed